bamlanivimab

Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 | Eli Lilly and Company

Eli Lilly and Company - 09 Nov 2020
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 | Eli Lilly and Company ...

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

The New England Journal of Medicine - 14 Jul 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 ...

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Nature - 22 Aug 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 ...

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Reuters - 16 Apr 2021
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab ...

Bamlanivimab not easy to pronounce, but provides Texas hospitals new COVID treatment

San Antonio News, Weather, Sports, Breaking News - 16 Nov 2020
Bamlanivimab not easy to pronounce, but provides Texas hospitals new COVID treatment ...

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

ScienceDirect.com - 20 Jul 2021
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination ...

EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly

European Medicines Agency - 02 Nov 2021
EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly ...

Bamlanivimab (LY-Cov555) for the Treatment of COVID-19, USA

Clinical Trials Arena - 19 Nov 2020
Bamlanivimab (LY-Cov555) for the Treatment of COVID-19, USA ...

Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-19, drugmaker reports

USA Today - 21 Jan 2021
Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-19, drugmaker reports ...

Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12

Eli Lilly and Company - 03 Dec 2021
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 ...

Coronavirus antibody therapies explained

DW - 29 Jan 2021
Coronavirus antibody therapies explained ...

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

Nature - 26 Oct 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial ...

Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

Eli Lilly and Company - 21 Jan 2021
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents ...

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies | Scientific Reports

Nature - 12 Oct 2021
Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies | Scientific Reports ...

Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19

Eli Lilly and Company - 09 Feb 2021
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19 ...

Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

Eli Lilly and Company - 10 Mar 2021
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 ...

EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

Eli Lilly and Company - 05 Mar 2021
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union ...

Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

Eli Lilly and Company - 26 Oct 2020
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial ...

Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

Eli Lilly and Company - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. ...